New vax tech drives fund-raising surge

Cash-hungry biotech companies have been headed back to the market recently as investors' appetite for biotech stocks was whetted by Big Pharma's high-profile pursuit of new therapies and the bright spotlight now focused on new vaccine technologies. Fund-raising has spiked 36 percent so far this year, says Thomson Reuters, with 39 debt offerings delivering $5.7 billion to an industry that has been starving for fresh capital. Report

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.